High-throughput affinity denaturation assay for constructing drug target space
Ontology highlight
ABSTRACT:
ORGANISM(S): Homo Sapiens (human)
SUBMITTER: Mingliang Ye
PROVIDER: PXD025669 | JPOST Repository | Wed Apr 28 00:00:00 BST 2021
REPOSITORIES: jPOST
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| HF_RCF20200612_heat52_Stau_1.raw | Raw | |||
| HF_RCF20200612_heat52_Stau_2.raw | Raw | |||
| HF_RCF20200612_heat52_Stau_3.raw | Raw | |||
| HF_RCF20200612_heat52_Stau_4.raw | Raw | |||
| HF_RCF20200612_heat52_Stau_5.raw | Raw |
Items per page: 5 1 - 5 of 20 |
Similar Datasets
Project description:Targeted proteomics data was acquired on a QE-HF mass spectrometer with data-independent acquisition (DIA) model.
2021-03-28 | PXD025037 | JPOST Repository
Project description:Targeted proteomics data was acquired on a QE-HF mass spectrometer with data-independent acquisition (DIA) model.
2022-01-10 | PXD025039 | JPOST Repository
Project description:Identifying the molecular targets for the beneficial or detrimental effects of small-molecule drugs is an important and currently unmet challenge. We have developed a method, drug affinity responsive target stability (DARTS), which takes advantage of a reduction in the protease susceptibility of the target protein upon drug binding. DARTS is universally applicable because it requires no modification of the drug and is independent of the mechanism of drug action. We demonstrate use of DARTS to identify known small-molecule-protein interactions and to reveal the eukaryotic translation initiation machinery as a molecular target for the longevity-enhancing plant natural product resveratrol. We envisage that DARTS will also be useful in global mapping of protein-metabolite interaction networks and in label-free screening of unlimited varieties of compounds for development as molecular imaging agents.
| S-EPMC2789755 | biostudies-literature
Project description:MotivationThe identification of novel drug-target (DT) interactions is a substantial part of the drug discovery process. Most of the computational methods that have been proposed to predict DT interactions have focused on binary classification, where the goal is to determine whether a DT pair interacts or not. However, protein-ligand interactions assume a continuum of binding strength values, also called binding affinity and predicting this value still remains a challenge. The increase in the affinity data available in DT knowledge-bases allows the use of advanced learning techniques such as deep learning architectures in the prediction of binding affinities. In this study, we propose a deep-learning based model that uses only sequence information of both targets and drugs to predict DT interaction binding affinities. The few studies that focus on DT binding affinity prediction use either 3D structures of protein-ligand complexes or 2D features of compounds. One novel approach used in this work is the modeling of protein sequences and compound 1D representations with convolutional neural networks (CNNs).ResultsThe results show that the proposed deep learning based model that uses the 1D representations of targets and drugs is an effective approach for drug target binding affinity prediction. The model in which high-level representations of a drug and a target are constructed via CNNs achieved the best Concordance Index (CI) performance in one of our larger benchmark datasets, outperforming the KronRLS algorithm and SimBoost, a state-of-the-art method for DT binding affinity prediction.Availability and implementationhttps://github.com/hkmztrk/DeepDTA.Supplementary informationSupplementary data are available at Bioinformatics online.
| S-EPMC6129291 | biostudies-literature
Project description:gene expression profile in diaphragm (DIA), extensor digitorum longus (EDL) and extraocular (EOM) muscles of rats with actively induced experimentally acquired MG (EAMG) using Affymetrix rat RAE230 gene chip. Keywords: myasthenia gravis (MG), rats with actively induced experimentally acquired MG (EAMG)
2008-10-01 | GSE11465 | GEO
Project description:The computational prediction of interactions between drugs and targets is a standing challenge in drug discovery. State-of-the-art methods for drug-target interaction prediction are primarily based on supervised machine learning with known label information. However, in biomedicine, obtaining labeled training data is an expensive and a laborious process. This paper proposes a semi-supervised generative adversarial networks (GANs)-based method to predict binding affinity. Our method comprises two parts, two GANs for feature extraction and a regression network for prediction. The semi-supervised mechanism allows our model to learn proteins drugs features of both labeled and unlabeled data. We evaluate the performance of our method using multiple public datasets. Experimental results demonstrate that our method achieves competitive performance while utilizing freely available unlabeled data. Our results suggest that utilizing such unlabeled data can considerably help improve performance in various biomedical relation extraction processes, for example, Drug-Target interaction and protein-protein interaction, particularly when only limited labeled data are available in such tasks. To our best knowledge, this is the first semi-supervised GANs-based method to predict binding affinity.
| S-EPMC6962343 | biostudies-literature
Project description:Determining and understanding drug target engagement is critical for drug discovery. This can be challenging within living cells as selective readouts are often unavailable. Here we describe a novel method for measuring target engagement in living cells based on the principle of altered protein thermal stabilization / destabilization in response to ligand binding. This assay (HCIF-CETSA) utilizes high content, high throughput single cell immunofluorescent detection to determine target protein levels following heating of adherent cells in a 96 well plate format. We have used target engagement of Chk1 by potent small molecule inhibitors to validate the assay. Target engagement measured by this method was subsequently compared to target engagement measured by two alternative methods (autophosphorylation and CETSA). The HCIF-CETSA method appeared robust and a good correlation in target engagement measured by this method and CETSA for the selective Chk1 inhibitor V158411 was observed. However, these EC50 values were 23- and 12-fold greater than the autophosphorylation IC50. The described method is therefore a valuable advance in the CETSA method allowing the high throughput determination of target engagement in adherent cells.
| S-EPMC5884524 | biostudies-literature
Project description:This repository is related to the work "Benchmarking commonly usedsoftware suites and analysis workflows for DIA proteomics and phosphoproteomics". The following files are stored here: 1. four MS datasets generated in this work, including two two-species benchmark datasets acquired on QE HF and timsTOF Pro, and two TNF-alpha induced phosphoproteomics datasets acquired on QE HF-X and timsTOF Pro; 2. all spectral libraries used in this work; 3. raw MS data search reports with analysis logs included if software reported; 4. preprocessed MS data search reports for any result from HF and TIMS DIA benchmark datasets; 5. FASTAs used in this work; 6. a description file (Description_of_iProX_and_public_data.xlsx) for the stored files in this repository and other public data used in this work. Note: 3 and 4 are packed into one zip file for each data search experiment.
2022-12-08 | PXD034709 |
Project description:Background Several computational advances have been achieved in the drug discovery field, promoting the identification of novel drug–target interactions and new leads. However, most of these methodologies have been overlooking the importance of providing explanations to the decision-making process of deep learning architectures. In this research study, we explore the reliability of convolutional neural networks (CNNs) at identifying relevant regions for binding, specifically binding sites and motifs, and the significance of the deep representations extracted by providing explanations to the model’s decisions based on the identification of the input regions that contributed the most to the prediction. We make use of an end-to-end deep learning architecture to predict binding affinity, where CNNs are exploited in their capacity to automatically identify and extract discriminating deep representations from 1D sequential and structural data. Results The results demonstrate the effectiveness of the deep representations extracted from CNNs in the prediction of drug–target interactions. CNNs were found to identify and extract features from regions relevant for the interaction, where the weight associated with these spots was in the range of those with the highest positive influence given by the CNNs in the prediction. The end-to-end deep learning model achieved the highest performance both in the prediction of the binding affinity and on the ability to correctly distinguish the interaction strength rank order when compared to baseline approaches. Conclusions This research study validates the potential applicability of an end-to-end deep learning architecture in the context of drug discovery beyond the confined space of proteins and ligands with determined 3D structure. Furthermore, it shows the reliability of the deep representations extracted from the CNNs by providing explainability to the decision-making process. Supplementary Information The online version contains supplementary material available at 10.1186/s12859-022-04767-y.
| S-EPMC9204982 | biostudies-literature
Project description:Here we demonstrate PfSTART1 engagement by WEHI991 in the P. falciparum proteome using organic solvent-based Proteome Integral Solubility Alteration (Solvent PISA) assay coupled with Data Independent Acquisition Mass Spectrometry (DIA-MS).
2024-05-01 | PXD048262 | JPOST Repository